Company Analysis
Sign in

Cue Biopharma, Inc. (CUE)

Nasdaq: CUE · Pharmaceutical Preparations · Boston, MA · filing with the SEC since 2015
Full chart Alerts Compare
Grade4.8
◀ Past 4.0● Present 4.0▶ Future 6.7
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenue$27.5M+195.7%
Net income-$26.6M+34.6%
Earnings per share$-0.28+61.1%
Operating cash flow-$21.7M+40.3%
Cash$27.1M+20.8%
Debtn/a
Shareholders’ equity$26.4M+51.0%
Shares, diluted94.7M+68.2%
Return on equity-100.6%
The recordfrom its filings
Filings in 202691
Newest filingNov 10 · SCHEDULE 13G/A
Annual reportMar 16, 2026
Quarterly reportAug 14, 2026
Next report due10-Q by Nov 14
Insider sales, 12 months$2.4M
Insider buys, 12 months$100,000
Patents granted32
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Jun 2026Revenue $37.7MNet income -$164MCash from operations -$50.0Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
171819202122232425
As filed, in USD. Nothing here is a forecast.

News

Oct 14, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Oct 14, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Oct 14, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Sep 21, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton CUE · research, not advice